BTIG raised the firm’s price target on GE HealthCare (GEHC) to $87 from $82 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others “left for dead”, BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare price target raised to $89 from $86 at Citi
- GE HealthCare to present portfolio of precision care at SNMMI
- Positive Outlook for GE Healthcare Technologies Amid Strong U.S. Hospital Expenditure and Global Stabilization
- GE Healthcare Issues $1.5 Billion in Senior Notes
- GE Healthcare Announces $1.5 Billion Notes Offering
